Skip to content
Screener

Immunovant, Inc. IMVT Business Segments — Other segment items

Similar metrics at other companies

Broadridge Financial Solutions logo
BRTotal Reportable Segments — Other segment items
$121.4M+7.5%
Iron Mountain logo
IRMTOTAL REPORTABLE SEGMENTS — Other segment items
$938.34M+13.0%
CNN
CNNETotal Reportable Segments — Other segment items
$17.4M+89.1%
GLW
GLWTotal Reportable Segments — Other segment items
$2.77B+16.4%
RCI Hospitality Holdings logo
RICKReportable Segments Excluding Other — Other segment items
$0-100%
Veradermics logo
MANEReportable Segment — Other segment items
-$2.63M-411%

Other financials

Income statement

See full
Net income-$147.9M-38.9%
EPS (diluted)-$0.73-15.9%

Balance sheet

See full
Cash & equivalents$902.1M+26.4%
Total debt$72.0K-26.5%
Total equity$852.6M+20.5%
Total assets$957.0M+23.3%

Cash flow

See full
Operating cash flow-$95.1M+14.1%
CapEx$8.0K-96.0%
Free cash flow-$95.1M+14.2%

Valuation

See full
Market cap$8.21B+201%
Enterprise value$7.31B+89.7%

Returns & leverage

See full
Return on equity-64.8%+2.5pp
Debt / equity0.0×
Current ratio9.1×-2.1×

Where this comes from

Reported directly by Immunovant, Inc. in its filing.

Tagged under the XBRL concept us-gaap:SegmentReportingOtherItemAmount.

The source filing: Immunovant, Inc.’s 10-K, filed May 20, 2026.

Filed
May 20, 2026, 7:28 AM EDT
Fiscal year
FY2026
Accession
0001764013-26-000064
Line itemYears Ended March 31, 2026Years Ended March 31, 2025Years Ended March 31, 2024
Contractual costs related to batoclimab program discontinuation38,952
Personnel-related research and development (1)128,534111,49974,290
Acquired in-process research and development12,500
Personnel-related general and administrative (2)48,73041,09534,684
Other general and administrative (3)27,51236,14022,597
Interest income, net(25,330)(24,732)(24,948)
Other segment items (4)(1,966)4201,575
Net loss$505,606$413,840$259,336

Item 8. Financial Statements and Supplementary Data

FAQ

What is Immunovant, Inc.'s business segments — other segment items?
Immunovant, Inc. (IMVT) reported business segments — other segment items of -$3.64M in Q1 2026.
What is the long-term trend for Immunovant, Inc.'s business segments — other segment items?
Over 2 years (2023 to 2026), Immunovant, Inc.'s business segments — other segment items has grown at a 173.9% compound annual growth rate (CAGR), from $262K to -$1.97M.
What does business segments — other segment items mean?
Includes miscellaneous income or expense items that do not fit into standard operating categories like R&D or G&A. These items often represent non-recurring or peripheral financial events specific to the segment's operations. Investors monitor this to identify one-time adjustments or unusual financial impacts that could distort core performance metrics.

Ask your AI about Immunovant, Inc.'s business segments — other segment items.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude